A new report from the generic drug lobby warns consumers and patients could lose $234 billion in total health care savings over the next 10 years unless policymakers eradicate barriers to generic drug and biosimilar access, such as outdated regulatory hurdles that slow the development and market entry, patent practices commonly used by brand drug companies to delay to competition and extend market monopolies, formulary practices that incentivize preferred treatment for expensive brand drugs, and unintended consequences of Inflation Reduction Act placed upon generic and biosimilar medicines.